公开(公告)号：US20230173048A1

公开(公告)日：2023-06-08

申请号：US17921837

申请日：2021-04-28

Applicant: The Institute of Cancer Research: Royal Cancer Hospital

Inventor： Stephen Pettitt ,  Christopher Lord ,  Marco Punta ,  Alan Melcher

IPC: A61K39/00 ,  C12N15/90 ,  C12N15/86 ,  A61K35/17 ,  A61P35/00

CPC classification number: A61K39/0011 ,  C12N15/902 ,  C12N15/86 ,  A61K35/17 ,  A61P35/00

Abstract: The present invention provides an anti-cancer vaccine comprising: (i) at least one peptide comprising the amino acid sequence of a neoantigen encoded by a mutant homologous recombination (HR) DNA repair gene selected from the group: BRCA1, BRCA2, PALB2, CDK12, RAD51B, RAD51C and RAD51D, wherein the mutant gene comprises a reversion mutation; and/or (ii) at least one polynucleotide encoding the at least one peptide of (i). Also provided are engineered T cells that recognise said neoantigen. Related methods and medical uses of the vaccine and/or engineered T cell are provided, including for the treatment of cancers, such as homologous recombination (HR) deficient cancers that acquire PARP inhibitor resistance or platinum resistance by development of reversion mutations in an HR DNA repair gene selected from the group: BRCA1, BRCA2, PALB2, CDK12, RAD51B, RAD51C and RAD51D.